Tozasertib (VX-680, MK-0457)

For research use only. Not for use in humans.

目录号:S1048 中文名称:陶扎色替

Tozasertib (VX-680, MK-0457) Chemical Structure

CAS No. 639089-54-6

Tozasertib (VX-680, MK-0457)是一种pan-Aurora抑制剂,对Aurora A作用最强,无细胞试验中Kiapp为0.6 nM,而对Aurora B/Aurora C的作用较弱,对Aurora A选择性比其他55种激酶高100倍。唯二的例外是 Fms-related tyrosine kinase-3 (FLT-3)BCR-ABL tyrosine kinase,也可被 Tozasertib 抑制,对应的Ki值均为30 nM和30 nM。Tozasertib 可诱导凋亡和自噬。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1098.34 现货
RMB 1211.51 现货
RMB 3017.92 现货
RMB 3833.09 现货
RMB 4316.13 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Tozasertib (VX-680, MK-0457)发表文献96篇:

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述 Tozasertib (VX-680, MK-0457)是一种pan-Aurora抑制剂,对Aurora A作用最强,无细胞试验中Kiapp为0.6 nM,而对Aurora B/Aurora C的作用较弱,对Aurora A选择性比其他55种激酶高100倍。唯二的例外是 Fms-related tyrosine kinase-3 (FLT-3)BCR-ABL tyrosine kinase,也可被 Tozasertib 抑制,对应的Ki值均为30 nM和30 nM。Tozasertib 可诱导凋亡和自噬。Phase 2。
靶点
Aurora A [1]
(Cell-free assay)
Aurora C [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
FLT3 [4]
(Cell-free assay)
Bcr-Abl [4]
(Cell-free assay)
0.6 nM(Ki app) 4.6 nM(Ki app) 18 nM(Ki app) 30 nM(Ki) 30 nM(Ki)
体外研究

虽然VX-680具有多激酶特性,VX-680却诱导相似的细胞毒性,IC50约为300 nM,在G2/M期,核内复制期,及转染ABL或FLT-3激酶的BaF3细胞凋亡时,显示一个Aurora B 类似的抑制表现型。VX-680抑制CAL-62细胞增殖,这种作用存在时间依赖性。用VX-680处理14天,明显降低群体的数量和大小,处理8305C下降达到70%,处理CAL-62, 8505C,和BHT-101下降达到90%。用VX-680处理不同ATC细胞,抑制细胞增殖,IC50为25到150  nM,这种作用存在时间和剂量依赖性。在软琼脂中,VX-680明显削弱不同细胞系形成群落的能力。caspase-3的活性分析显示VX-680诱导不同细胞凋亡。VX-680处理CAL-62 细胞12小时,形成DNA含量≥4N细胞累积物。微速摄影分析显示VX-680处理的CAL-62细胞离开细胞中期。VX-680可以抑制组蛋白H3的磷酸化作用。[2] VX-680作用于携带T315I突变的BCR-Abl的病人样本,具有明显抑制活性。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BE-13 NWPrW4RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LudmlEPTB;MD6wNFM{QCEQvF2= NGP1SmVUSU6JUlXS
RS4-11 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO2TWM2OD1yLkCwOFA1KM7:TR?= MXnTRW5IWkWU
MFH-ino MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X5bWlEPTB;MD6wNFk6KM7:TR?= NWSzU2FmW0GQR2LFVi=>
NTERA-S-cl-D1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDqPWVKSzVyPUCuNFE1OzRizszN NUXnVY8zW0GQR2LFVi=>
697 NVHYe3ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPrS5hyUUN3ME2wMlAzPDdzIN88US=> NYTIPJh[W0GQR2LFVi=>
NALM-6 NWLJV2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDDd49{UUN3ME2wMlAzPTV{IN88US=> M1;FSXNCVkeURWK=
ES8 NGHCOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TvbWlEPTB;MD6wOFYyOyEQvF2= MlzxV2FPT1KHUh?=
HUTU-80 NXvldXlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMEWyPVkh|ryP M1HKeHNCVkeURWK=
MV-4-11 M2fleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3yzOGlEPTB;MD6wO|c5OiEQvF2= MUnTRW5IWkWU
MONO-MAC-6 NEfzdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMEe4O|kh|ryP MVfTRW5IWkWU
LC-2-ad NEn5U5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly1TWM2OD1yLkC4O|g6KM7:TR?= NITvZY9USU6JUlXS
BL-41 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMUC0OFUh|ryP MYXTRW5IWkWU
A4-Fuk Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj2TnBKSzVyPUCuNVE2PjNizszN MXPTRW5IWkWU
SW954 NIn1ZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7PSFhKSzVyPUCuNVIzOjlizszN NEDrbXhUSU6JUlXS
BV-173 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzSOY1NUUN3ME2wMlEzPjRzIN88US=> M3HjeHNCVkeURWK=
TE-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH2xfWhKSzVyPUCuNVQ6QDJizszN NVXxdGtvW0GQR2LFVi=>
SK-UT-1 M2\odWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMUW5OlUh|ryP M4\VZnNCVkeURWK=
SIG-M5 NH;ZV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL4c4lKSzVyPUCuNVY4ODdizszN MmXrV2FPT1KHUh?=
OCUB-M NI\ucodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMU[5PFMh|ryP NETOd2JUSU6JUlXS
K052 M4D0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrHTWM2OD1yLkG5OFgh|ryP NIj1OFhUSU6JUlXS
VA-ES-BJ NX;JdYtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W3RWlEPTB;MD6yNFA5PiEQvF2= MoOwV2FPT1KHUh?=
SW982 NULx[WQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NISxWGlKSzVyPUCuNlE{QCEQvF2= NInHcXJUSU6JUlXS
LB647-SCLC NYnQco9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHNTWM2OD1yLkKxOVI{KM7:TR?= MUjTRW5IWkWU
PSN1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3GSVU2UUN3ME2wMlIzODJ4IN88US=> MnXTV2FPT1KHUh?=
BB30-HNC M3PHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDadYlPUUN3ME2wMlIzPTlzIN88US=> MmLyV2FPT1KHUh?=
ST486 NWDmXVBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILzW3FKSzVyPUCuNlMxQDdizszN NIPoUIJUSU6JUlXS
MOLT-4 NUnSZoE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGOxS4ZKSzVyPUCuNlM{OzdizszN M2DrWnNCVkeURWK=
EW-16 MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofnTWM2OD1yLkKzO|Y5KM7:TR?= Ml\VV2FPT1KHUh?=
KS-1 NEHoUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfiUoNlUUN3ME2wMlI{Pzh3IN88US=> MnzVV2FPT1KHUh?=
SR M3\4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfDR3NKSzVyPUCuNlQ2PjRizszN MYrTRW5IWkWU
KM12 M3G3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O0WGlEPTB;MD6yOlM3KM7:TR?= MYHTRW5IWkWU
EM-2 M{Tn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\wTWM2OD1yLkK2OlQyKM7:TR?= NWOycoVbW0GQR2LFVi=>
MEG-01 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Dn[GlEPTB;MD6yO|g1QSEQvF2= MWfTRW5IWkWU
NB13 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjPeYNKSzVyPUCuNlc6QDRizszN NXrlVo9PW0GQR2LFVi=>
RKO M2jwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXKV3BKUUN3ME2wMlMxQDF|IN88US=> NE\DVZVUSU6JUlXS
CESS MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnlTWM2OD1yLkOxN|I5KM7:TR?= NFjJS4NUSU6JUlXS
EoL-1-cell NHPPfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwM{O0OVkh|ryP NXGzbGRSW0GQR2LFVi=>
DOHH-2 NFrPb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e1emlEPTB;MD6zN|c5OSEQvF2= MWXTRW5IWkWU
A388 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXG[ohKSzVyPUCuN|QxQDZizszN M3nxTXNCVkeURWK=
LAMA-84 NIXqZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO4NoVqUUN3ME2wMlM2OTd6IN88US=> MmLpV2FPT1KHUh?=
IMR-5 NUm2Um9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\pTWM2OD1yLkO1OVQh|ryP NE\vTJVUSU6JUlXS
KARPAS-422 M{HUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm1OmhKSzVyPUCuN|czPzJizszN MVrTRW5IWkWU
MRK-nu-1 NW\L[mhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjaTWM2OD1yLkO4NVMh|ryP MVfTRW5IWkWU
BL-70 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwM{i5O|Qh|ryP MVjTRW5IWkWU
LXF-289 NFzhWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLNSGt4UUN3ME2wMlQxPDB4IN88US=> MYPTRW5IWkWU
RL95-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfFZm5KSzVyPUCuOFA2PjdizszN Mn7HV2FPT1KHUh?=
QIMR-WIL M4rHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLD[3ZKSzVyPUCuOFI3PzZizszN NXrtO3J[W0GQR2LFVi=>
K-562 NVqyOFZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULJU3R3UUN3ME2wMlQ{PDd{IN88US=> MUfTRW5IWkWU
NCI-H510A NX;hO|lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrZTWM2OD1yLkSzPFI{KM7:TR?= MoSxV2FPT1KHUh?=
NCI-H524 MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ZTWM2OD1yLkWxNVQ4KM7:TR?= M1zxbHNCVkeURWK=
KE-37 MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDhTWM2OD1yLkWyNVAzKM7:TR?= MlLwV2FPT1KHUh?=
KP-N-YS Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHqdoRzUUN3ME2wMlU1Ozl{IN88US=> NF3VdIdUSU6JUlXS
LS-411N NVL3Z2pzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHWOG9KSzVyPUCuOVc4PTJizszN MY\TRW5IWkWU
CTV-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XRS2lEPTB;MD61PFc4OyEQvF2= NVPidW5GW0GQR2LFVi=>
NCI-SNU-16 M{KwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvKdIhKSzVyPUCuOlM2PzFizszN NH\nW3VUSU6JUlXS
HT-144 NUnx[IFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XtR2lEPTB;MD62N|c6QCEQvF2= NHLkfItUSU6JUlXS
NCI-H187 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[2N2lEPTB;MD62OFE{KM7:TR?= MWfTRW5IWkWU
OCI-AML2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ew[GlEPTB;MD62OFQxOyEQvF2= MkDpV2FPT1KHUh?=
CCRF-CEM MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjrTWM2OD1yLk[1N|Q3KM7:TR?= MkjsV2FPT1KHUh?=
ONS-76 NILCNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwNk[0OVgh|ryP M2H1UnNCVkeURWK=
IST-SL2 M4THZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHxO5ZsUUN3ME2wMlcyQTh{IN88US=> M3O0NnNCVkeURWK=
NB6 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwN{eyOVQh|ryP MVvTRW5IWkWU
SK-PN-DW NHvJWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL5S3ZUUUN3ME2wMlc6OTRizszN NVHIWHRXW0GQR2LFVi=>
HCC1599 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXSTWM2OD1yLkiwPFc1KM7:TR?= NUDNWHpLW0GQR2LFVi=>
MC116 NFvsTYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHUS2VIUUN3ME2wMlg2ODFzIN88US=> MV;TRW5IWkWU
TE-15 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFftXpdKSzVyPUCuPFUxQThizszN M3vjPHNCVkeURWK=
HOP-62 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHVTWM2OD1yLki2N|I6KM7:TR?= NXTXUZllW0GQR2LFVi=>
TGBC24TKB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwOE[zPFUh|ryP MmPQV2FPT1KHUh?=
HCE-4 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInDXGhKSzVyPUCuPFgxPjNizszN MmHoV2FPT1KHUh?=
ALL-PO MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Px[mlEPTB;MD64PFE4PSEQvF2= MmixV2FPT1KHUh?=
KGN NVXPPVRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\DdWlEPTB;MD64PVk6PSEQvF2= M3vURXNCVkeURWK=
ML-2 NYHuNJVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvaTWM2OD1yLkmwNlU6KM7:TR?= MX3TRW5IWkWU
ES4 M4HtfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\HTWM2OD1yLkmxNVI5KM7:TR?= M2PFO3NCVkeURWK=
SF126 Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi3eWJSUUN3ME2wMlk1QDF7IN88US=> NEm3c4NUSU6JUlXS
SK-N-DZ NWX3PWE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXLNJZxUUN3ME2wMlk3OTh7IN88US=> NGTlUJVUSU6JUlXS
HCC1187 NIHmS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;jT5FKSzVyPUGuNFA2ODVizszN NVr4VHp1W0GQR2LFVi=>
DU-4475 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLVTWM2OD1zLkCxO|U3KM7:TR?= NFO5VGtUSU6JUlXS
NKM-1 NVLHdIkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTZVWpvUUN3ME2xMlAzPzd3IN88US=> Mli1V2FPT1KHUh?=
HL-60 NV\1b|ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jNVmlEPTB;MT6wOlU4PCEQvF2= MmXkV2FPT1KHUh?=
SBC-1 NH;SN4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTOTWM2OD1zLkGyOVQzKM7:TR?= Ml7QV2FPT1KHUh?=
TE-10 Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:wT4FPUUN3ME2xMlEzQTR4IN88US=> NY[5O|c1W0GQR2LFVi=>
ETK-1 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwMUO2NVMh|ryP NVvZ[HFvW0GQR2LFVi=>
HAL-01 NXzDOFhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjk[YRKSzVyPUGuNVY4ODlizszN NFezT45USU6JUlXS
BB65-RCC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HWbGlEPTB;MT6xPFAxPSEQvF2= NWn3UHB[W0GQR2LFVi=>
EW-1 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\DTWM2OD1zLkG4OVYzKM7:TR?= MnziV2FPT1KHUh?=
SK-NEP-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFwMkGxNVEh|ryP M2[5b3NCVkeURWK=
SK-LMS-1 Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED1[lJKSzVyPUGuNlIzOTJizszN M1y3cXNCVkeURWK=
DEL M4HPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwMkW2OFMh|ryP M{DVcnNCVkeURWK=
GT3TKB MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFwMkiwOVch|ryP NVfncHNyW0GQR2LFVi=>
MOLT-16 M3PCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwM{W0NFUh|ryP NF7QdmdUSU6JUlXS
CMK MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nVT2lEPTB;MT60NlEyPyEQvF2= NX7iXFJZW0GQR2LFVi=>
NB5 M4nMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPLb|V7UUN3ME2xMlY1OjJ7IN88US=> NEC0O4xUSU6JUlXS
NCI-H1963 NEjHSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fWWGlEPTB;MT63NFU5OyEQvF2= MYPTRW5IWkWU
KURAMOCHI MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLCTWM2OD1zLke4PVEyKM7:TR?= MW\TRW5IWkWU
TE-8 NHPENFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFwOECzOlgh|ryP NEXNcYpUSU6JUlXS
NCI-H1304 NWL1c|NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjBRZZDUUN3ME2xMlg{ODd|IN88US=> MmXWV2FPT1KHUh?=
A101D M2nE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwOEezPVUh|ryP M1GzV3NCVkeURWK=
SCLC-21H NHrBcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFwOUewOVch|ryP MUDTRW5IWkWU
GB-1 M4j6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvqOG5KSzVyPUKuNFE3PDdizszN M1\LWnNCVkeURWK=
KARPAS-45 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJwMEK2OVQh|ryP NH3ESGhUSU6JUlXS
ATN-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO4OGFKSzVyPUKuNFI5PThizszN NHvYTJRUSU6JUlXS
NCI-H720 M{CzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;6TWM2OD1{LkC2NlQ1KM7:TR?= NHK2VYdUSU6JUlXS
RPMI-6666 NXPT[IJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULzXG9sUUN3ME2yMlE3OjB5IN88US=> MnfxV2FPT1KHUh?=
NB17 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13hVWlEPTB;Mj6yPVI4KM7:TR?= M2jDd3NCVkeURWK=
IST-SL1 MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYmxXmVpUUN3ME2yMlI6PzZ3IN88US=> M3W3SHNCVkeURWK=
SH-4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjYSohKSzVyPUKuN|I1PjlizszN NEHNWpBUSU6JUlXS
K5 M322SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLzXWpnUUN3ME2yMlQxOzF7IN88US=> NWDTRWx2W0GQR2LFVi=>
OVCAR-4 NWjy[lFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmToTWM2OD1{LkS2NVMh|ryP NX\yPVFoW0GQR2LFVi=>
ACN NEGxb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDCdYM2UUN3ME2yMlUxOjF|IN88US=> NGTXdJBUSU6JUlXS
TGW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXYO4ZDUUN3ME2yMlY2QDN{IN88US=> NGH5bVFUSU6JUlXS
NCI-H2107 M1uyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq3TWM2OD1{LkizO|EyKM7:TR?= NIHHfIJUSU6JUlXS
NCI-H82 NFrhXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwOEO4N|gh|ryP MlXiV2FPT1KHUh?=
SK-N-FI Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3ldItpUUN3ME2yMlg3QDZ6IN88US=> Mo\nV2FPT1KHUh?=
LB1047-RCC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KzcmlEPTB;Mj64PFEzPiEQvF2= M2fMO3NCVkeURWK=
LU-134-A MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnwdIdFUUN3ME2yMlg6OjZizszN NF76SotUSU6JUlXS
NCI-H209 NI\nVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwOUGyOVMh|ryP NV2wPGxsW0GQR2LFVi=>
NOMO-1 M{TJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTNwMEKyO|Qh|ryP MlnBV2FPT1KHUh?=
RH-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjT[2NKSzVyPUOuNVczQTFizszN NXHwO5pKW0GQR2LFVi=>
LOUCY MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV63eVVTUUN3ME2zMlE5Pjl|IN88US=> MX;TRW5IWkWU
TE-9 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi2cmZiUUN3ME2zMlI3PzN4IN88US=> MmTPV2FPT1KHUh?=
PF-382 M{PCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTNwM{W3O|gh|ryP MkDWV2FPT1KHUh?=
RPMI-8402 MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LwSGlEPTB;Mz61PFYxOyEQvF2= MlzoV2FPT1KHUh?=
HEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK4eGxKSzVyPUOuOlMzKM7:TR?= NV23e4hWW0GQR2LFVi=>
NOS-1 M1XGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHlV2pGUUN3ME2zMlg1PzV2IN88US=> M1PaUnNCVkeURWK=
ES1 NVy2cm1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTNwOUKyPVMh|ryP M2Ww[nNCVkeURWK=
NCI-H2171 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom3TWM2OD1|LkmyOFI{KM7:TR?= MYnTRW5IWkWU
NCI-H747 NUj0WmdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LOUmlEPTB;Mz65OFIzOSEQvF2= NUHa[4pIW0GQR2LFVi=>
MHH-NB-11 NYGxZ2dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe3U4JVUUN3ME2zMlk2OzF{IN88US=> MoiyV2FPT1KHUh?=
MZ1-PC Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\XfpdNUUN3ME2zMlk6OjRizszN M3;UbXNCVkeURWK=
MMAC-SF NI[wTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTRwMEK0Olch|ryP NGDHUItUSU6JUlXS
NMC-G1 M1v0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;q[lBKSzVyPUSuNlI4OjNizszN Ml;2V2FPT1KHUh?=
SW872 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\tdGNPUUN3ME20MlM1OzRizszN NUjU[3hoW0GQR2LFVi=>
TE-12 NYT4fIxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH3fWF[UUN3ME20MlU3Ozl2IN88US=> MXzTRW5IWkWU
LU-139 NHfhTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTRwNkG4N|Uh|ryP NUfpfFZlW0GQR2LFVi=>
HC-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jrXmlEPTB;ND62PVQ6PCEQvF2= MULTRW5IWkWU
COR-L279 M2rDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\JUGlEPTB;ND63OVg6OSEQvF2= NGrK[INUSU6JUlXS
SF268 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X4bGlEPTB;ND63PVkyPiEQvF2= NXvaNVQ1W0GQR2LFVi=>
MC-CAR NYmzW|c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTVwME[3OVch|ryP MXvTRW5IWkWU
TK10 M3Ozc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHpRXdKSzVyPUWuN|U1PjlizszN NEL5fJpUSU6JUlXS
TE-1 M37VXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fkXmlEPTB;NT60PVAxPCEQvF2= MYPTRW5IWkWU
NCI-H2126 NVvpUoRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ja[GlEPTB;NT62OFU4PCEQvF2= MVfTRW5IWkWU
Daudi NGGzSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:yUGlEPTB;NT62PVEzKM7:TR?= M1q4SXNCVkeURWK=
NCI-H1648 M2XwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTVwOEG0OVQh|ryP NFeySWlUSU6JUlXS
OS-RC-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzXTWM2OD13Lkm4OVk4KM7:TR?= M{HJS3NCVkeURWK=
DJM-1 NI\FW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHCdWJKSzVyPU[uN|Q3PjZizszN NEewbJRUSU6JUlXS
LS-1034 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTZwN{W2OkDPxE1? MlG1V2FPT1KHUh?=
NCI-H1581 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\FR2lEPTB;Nj63PFQxPSEQvF2= MXvTRW5IWkWU
UACC-257 NUPZSnZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTLcWdpUUN3ME23MlA1PTF{IN88US=> MUPTRW5IWkWU
KM-H2 NHHPXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jEN2lEPTB;Nz6xPFQ2PyEQvF2= M3TqXnNCVkeURWK=
NCI-H1436 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTdwNkm5N|Ih|ryP M{jBRnNCVkeURWK=
IA-LM MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjjTnBKSzVyPUeuPFU6KM7:TR?= NXHW[o9kW0GQR2LFVi=>
NCI-H526 NW[ydYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nvS2lEPTB;OD6yOVY{PyEQvF2= MWjTRW5IWkWU
GCIY MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG3TWM2OD16LkO2PVY2KM7:TR?= MkLjV2FPT1KHUh?=
CP67-MEL M2fjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRThwNUOyOkDPxE1? M4jhPXNCVkeURWK=
KALS-1 MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\ZTWM2OD16LkizPFUyKM7:TR?= NHX2clFUSU6JUlXS
NCI-H1770 M{DZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRThwOUCyOlUh|ryP NH7xb4hUSU6JUlXS
8-MG-BA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrIVZVQUUN3ME25MlMzQDR2IN88US=> MVrTRW5IWkWU
KY821 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\kfVFKSzVyPUmuO|c1QDRizszN MUjTRW5IWkWU
SNB75 M1zLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zuNGlEPTB;MUCuNFc3KM7:TR?= MkniV2FPT1KHUh?=
NCCIT MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFzLkC1PFIh|ryP NXrQ[4ZMW0GQR2LFVi=>
SJSA-1 M{D1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm4TWM2OD1zMT6yPFkyKM7:TR?= MlLxV2FPT1KHUh?=
LB373-MEL-D NUfzcIhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;jT2lEPTB;MUGuN|gzPyEQvF2= M2q5R3NCVkeURWK=
TALL-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vvfWlEPTB;MUGuOFA2QCEQvF2= NGfHRnZUSU6JUlXS
NB69 NVf6fmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWizXVhkUUN3ME2xNU44PzB3IN88US=> NFfm[HVUSU6JUlXS
NCI-H1355 NFnEXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFzLkm0NlYh|ryP M2LSZ3NCVkeURWK=
DMS-153 M4[5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3vUndKSzVyPUGyMlA1OjZizszN NITa[WJUSU6JUlXS
OPM-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjTSmlKSzVyPUGyMlE2QTZizszN M1PqUXNCVkeURWK=
NB1 NEnaT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3OTWM2OD1zMj6yPUDPxE1? MkTFV2FPT1KHUh?=
A3-KAW NIXJdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzoTWM2OD1zMj6zNlM3KM7:TR?= MnuwV2FPT1KHUh?=
NCI-H1882 NHjucHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF{LkSwOlYh|ryP NXPneplpW0GQR2LFVi=>
KG-1 M3vqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTrTWM2OD1zMj62OVQ2KM7:TR?= MVLTRW5IWkWU
LC4-1 M{Ha[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7ZSXFZUUN3ME2xNk44PzB4IN88US=> Moe0V2FPT1KHUh?=
HCE-T M4HKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPPTWM2OD1zMz6wNFQ6KM7:TR?= MWPTRW5IWkWU
NEC8 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXER4hmUUN3ME2xN{4yODN6IN88US=> MnnJV2FPT1KHUh?=
IST-MEL1 M2rDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF|LkW3PFgh|ryP NVf5T2I3W0GQR2LFVi=>
EW-3 MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF|Lke0NFIh|ryP MYTTRW5IWkWU
CTB-1 NUXROnhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D3bGlEPTB;MUSuNFMzQSEQvF2= MYTTRW5IWkWU
LS-123 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF2LkG1PFgh|ryP MUPTRW5IWkWU
NCI-H1417 NVXWVIJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPBTWM2OD1zND6zNFUzKM7:TR?= MkX6V2FPT1KHUh?=
MZ7-mel NGDhPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF2LkS0N|Mh|ryP Mk\ZV2FPT1KHUh?=
JiyoyeP-2003 NX\VV4dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:xO4JKSzVyPUG1MlY{OjZizszN M3HUe3NCVkeURWK=
ES6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLOXVBKSzVyPUG2MlI{PjFizszN M1jseHNCVkeURWK=
HH MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LTdGlEPTB;MUeuNVk3OyEQvF2= M4fFdHNCVkeURWK=
SF539 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF5Lkm5NlIh|ryP NIq2WXlUSU6JUlXS
Calu-6 NVP4O2h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjnU4pJUUN3ME2xPU4zOzlizszN MkjvV2FPT1KHUh?=
SK-MM-2 NUO4cWdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv2co5KSzVyPUG5MlU2PSEQvF2= Moj1V2FPT1KHUh?=
IST-MES1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvBTWM2OD1zOT62OlY{KM7:TR?= NEP6WmxUSU6JUlXS
GI-ME-N M1\WOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPYOYhKSzVyPUG5MlgzOjdizszN MUDTRW5IWkWU
CAL-148 MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPSTWM2OD1{MD65PVM1KM7:TR?= MnOwV2FPT1KHUh?=
EVSA-T M13UR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7K[2tKSzVyPUKxMlE1QTlizszN NIn1fo1USU6JUlXS
LP-1 NU[wcWhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrnV5JKSzVyPUKxMlM1OzJizszN NXWwSXoxW0GQR2LFVi=>
BOKU MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfIfIxKSzVyPUKxMlQ2OzNizszN M{XLVHNCVkeURWK=
KLE M3XYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHOOotmUUN3ME2yNk4yQTB|IN88US=> MWfTRW5IWkWU
LB831-BLC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj5TWM2OD1{NT6xOVI3KM7:TR?= NWjDO4lYW0GQR2LFVi=>
NCI-H889 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ3LkG5N|Eh|ryP NEC5fHpUSU6JUlXS
REH NUPBOJBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ3LkS2O|Eh|ryP Mnm3V2FPT1KHUh?=
KP-N-RT-BM-1 M2WxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;OTWM2OD1{NT60O|UzKM7:TR?= NWPs[ZM{W0GQR2LFVi=>
MPP-89 M2K0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ3LkWzNVQh|ryP NGDBPGRUSU6JUlXS
no-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3WxRWlEPTB;MkWuO|Q4KM7:TR?= MkPYV2FPT1KHUh?=
NCI-H748 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ3Lke2Nlch|ryP MnTPV2FPT1KHUh?=
LB2518-MEL NETJVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXraOXV1UUN3ME2yO{4yPzd|IN88US=> NFfv[3lUSU6JUlXS
TGBC1TKB M3XYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ5LkW1PFUh|ryP MVXTRW5IWkWU
MHH-PREB-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJ6LkC3N|Qh|ryP NHfCcZhUSU6JUlXS
MZ2-MEL MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[3VGlEPTB;MkiuOlE1OyEQvF2= MmrSV2FPT1KHUh?=
U-266 NGX4NoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKyTWM2OD1{OD62N|Y3KM7:TR?= MX3TRW5IWkWU
SNU-C1 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LRTWlEPTB;MkiuPVQ{KM7:TR?= NI\k[4dUSU6JUlXS
SW962 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTNyLkK3OFch|ryP Mn3UV2FPT1KHUh?=
Raji MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPoTWM2OD1|MD61OVkzKM7:TR?= NUTVR2syW0GQR2LFVi=>
KNS-42 NIjRcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjJWmtjUUN3ME2zNE45QTV4IN88US=> MkG0V2FPT1KHUh?=
LB996-RCC NVu2VWNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHpTWM2OD1|MT6xO|AzKM7:TR?= NEflU2NUSU6JUlXS
CHP-126 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17GdWlEPTB;M{GuNVk5PCEQvF2= NWLUT2RWW0GQR2LFVi=>
RXF393 NVrVNI5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTN{LkS5O{DPxE1? MWLTRW5IWkWU
COLO-684 NFHxfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG0TWtKSzVyPUOyMlY1OzhizszN MkjLV2FPT1KHUh?=
A704 NFzFdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrVOYJwUUN3ME2zN{42PTN6IN88US=> NYHTOG9LW0GQR2LFVi=>
A253 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYKwbIRqUUN3ME2zN{42QDV{IN88US=> NYDXfVlPW0GQR2LFVi=>
KNS-81-FD MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLtblBjUUN3ME2zOE42PDV4IN88US=> NV;Ceot3W0GQR2LFVi=>
TE-441-T NULsN49QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PQdGlEPTB;M{SuOlM4OSEQvF2= M37lO3NCVkeURWK=
HCC2157 NVrBeHIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1eyXWlEPTB;M{WuOFYyQSEQvF2= MnrTV2FPT1KHUh?=
ES3 NGfNfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\Lbll{UUN3ME2zOk43PzVizszN NH\QUIpUSU6JUlXS
NCI-H1155 NULDXpVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjYOmlKSzVyPUO3MlgyPSEQvF2= M4qz[XNCVkeURWK=
SNU-C2B Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn3dnRLUUN3ME2zPE4yPjV2IN88US=> NX3uRotRW0GQR2LFVi=>
JAR M1nJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN6LkK0OFkh|ryP NIXCXYdUSU6JUlXS
GDM-1 M2jLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHTNXh6UUN3ME2zPE46OTF4IN88US=> NV3WfGxtW0GQR2LFVi=>
KU812 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV73fmt2UUN3ME20NU42ODdizszN NYntS2pPW0GQR2LFVi=>
BC-1 M37JRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W1Z2lEPTB;NEKuOlc{OSEQvF2= NHe1ZWpUSU6JUlXS
GI-1 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTR{LkmxPVIh|ryP MYnTRW5IWkWU
NCI-H1694 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ezfGlEPTB;NESuPVQ4OiEQvF2= NUfZc4R{W0GQR2LFVi=>
DG-75 NY\4epdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR3LkG1O|ch|ryP NYPz[IZYW0GQR2LFVi=>
COR-L88 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrldG9KSzVyPUS1MlI4PzhizszN NUH4N2xPW0GQR2LFVi=>
LS-513 M2HuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\WTWM2OD12NT65NVU3KM7:TR?= NXLXTWczW0GQR2LFVi=>
HD-MY-Z MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP0WG0xUUN3ME20Ok41PjF{IN88US=> NEjDNJJUSU6JUlXS
L-363 NX20R5hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\DVnJKSzVyPUS2Mlg5OSEQvF2= MYHTRW5IWkWU
TE-6 NWDxbFBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L4c2lEPTB;NEiuOFQ3KM7:TR?= MWDTRW5IWkWU
NCI-H345 NVfYb4hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\VcHpVUUN3ME20PE41PjhizszN M4LvNnNCVkeURWK=
TE-5 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPUTWM2OD12OT63NVE5KM7:TR?= M{O2fnNCVkeURWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DLK / p-MKK7 / MKK7 / p-JNK / JNK ; 

PubMed: 23431148     


Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. 

p-AURKA / AURKA / Survivin ; 

PubMed: 28218735     


BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. 

YAP; 

PubMed: 31160567     


Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. 

p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; 

PubMed: 21600017     


NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.

23431148 28218735 31160567 21600017
Immunofluorescence
α-tubulin / Aurora-A ; 

PubMed: 21600017     


The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.

21600017
Growth inhibition assay
Cell viability; 

PubMed: 21600017     


VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, *p < 0.05, **p < 0.01, compared to control.

21600017
体内研究 VX-680作用于人类AML(HL-60)移植瘤模型明显降低肿瘤尺寸。VX-680按75 mg/kg剂量给药实验鼠,每天腹腔注射两次,持续13天,与对照组相比,平均肿瘤体积下降达98%。肿瘤体积比实验之前初始体积小很多。按12.5 mg/kg剂量每天给药两次,肿瘤生长也明显降低,这种作用存在剂量依赖性。VX-680耐受性很好,只有在使用高剂量时可以观察到实验动物体重稍微降低。通过比较cisplatin,按5.4 mg/kg剂量给药,每四天腹腔注射一次,一共进行三次,抑制肿瘤生长只达9%。VX-680作用于胰脏和结肠移植瘤,也引起肿瘤衰退。VX-680静脉注射给药携带HCT116肿瘤的实验鼠,显示很强的抗癌活性。使用高剂量VX-680(每小时2 mg/kg)处理,明显提高效果,比实验钱的初始肿瘤平均尺寸下降56%。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[3]

- 合并

激酶抑制实验:

丙酮酸激酶/乳酸脱氢酶催化NADH的氧化,伴随着ATP的消耗,观察340 nm 处吸光值的降低。反应包括100 mM Tris (pH 为 8), 10 mM MgCl2, 2.2 mM ATP, 1 mM磷酸烯醇丙酮酸, 0.6 mg/ml NADH, 75 ml丙酮酸激酶, 105 ml 乳酸脱氢酶,和0.5 mM 基底肽(序列为EAIYAAPFAKKK)。加入足够的激酶开始反应,反应的激酶浓度达到30 nM,用微量滴定板分光光度计在30oC进行30分钟,观察吸收率的降低。通过加入3.75 μl 溶于100% DMSO的VX-680 或单独DMSO,获得抑制常数。按如下公式计算Ki值,Ki = IC50/(1+[S]/Kd),[S]=[ATP]=2.2 mM, Kd=70 μM。假定作用于野生型和H396P Abl 激酶域的Kd(ATP)为70 μM,计算以上各值。
细胞实验:

[2]

- 合并
  • Cell lines: CAL-62细胞
  • Concentrations: 5-500 nM
  • Incubation Time: 4天
  • Method:

    对照组CAL-62细胞培养在二甲亚砜和DMSO中,实验组加入500 nM VX-680,处理1到5天。加入不同浓度(5到500 nM) Aurora抑制剂处理不同ATC细胞4天,用来测定VX-680作用于细胞增殖的剂量依赖性。细胞在温育结束前加30 mM BrdU标记,脉冲2小时。通过比色免疫分析使用细胞增殖ELISA试剂盒分析BrdU的合并率。通过比较VX-680处理的细胞和对照组细胞得到结果,


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 右侧腋窝处皮下注射107 HL-60白血病细胞的雌性无胸腺NCr-nu鼠
  • Dosages: 50 mg/kg, 75 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 93 mg/mL (200.17 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+2% Tween 80+ddH2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 464.59
化学式

C23H28N8OS

CAS号 639089-54-6
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品

Tags: 购买Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457)供应商 | 采购Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457)价格 | Tozasertib (VX-680, MK-0457)生产 | 订购Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID